Nanotechnology-based Delivery Systems to Overcome Drug Resistance in Cancer

Overview

Journal Med Rev (2021)

Publisher De Gruyter

Specialty General Medicine

Date 2024 Mar 22

PMID 38515777

Authors

Harsh Patel

Jiaxin Li

Letao Bo

Riddhi Mehta

Charles R Ashby Jr

Shanzhi Wang

Wei Cai

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics. Multidrug resistance (MDR) in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure. There have been successes in the development of cancer nanomedicine to overcome MDR; however, relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer. This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells. Here, we discuss the advances, types of nanomedicines, and the challenges regarding the translation of to results and their relevance to effective therapies.

Citing Articles

LncRNA FAM30A Suppresses Proliferation and Metastasis of Colorectal Carcinoma by Blocking the JAK-STAT Signalling.

Liu J, Han S, Cui Y, Zhao Q, Wang Y, Li T J Cell Mol Med. 2025; 29(4):e70421.

PMID: 39972942 PMC: 11839745. DOI: 10.1111/jcmm.70421.

Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.

Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y Pharmaceutics. 2025; 16(12.

PMID: 39771528 PMC: 11728492. DOI: 10.3390/pharmaceutics16121549.

Harnessing the Power of Polyphenols: A New Frontier in Disease Prevention and Therapy.

El Oirdi M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931359 PMC: 11206774. DOI: 10.3390/ph17060692.

Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research.

Garg P, Pareek S, Kulkarni P, Salgia R, Singhal S J Clin Med. 2024; 13(12).

PMID: 38929995 PMC: 11204592. DOI: 10.3390/jcm13123466.

References

Barnard A . One-to-one comparison of sunscreen efficacy, aesthetics and potential nanotoxicity. Nat Nanotechnol. 2010; 5(4):271-4. DOI: 10.1038/nnano.2010.25. View

Ozpolat B, Sood A, Lopez-Berestein G . Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66:110-6. PMC: 4527165. DOI: 10.1016/j.addr.2013.12.008. View

Xu J, Wong D, Byrne J, Chen K, Bowerman C, DeSimone J . Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed Engl. 2013; 52(26):6580-9. PMC: 4157646. DOI: 10.1002/anie.201209145. View

Lv J, Zhang L, Du W, Ling G, Zhang P . Functional gold nanoparticles for diagnosis, treatment and prevention of thrombus. J Control Release. 2022; 345:572-585. DOI: 10.1016/j.jconrel.2022.03.044. View

Mocanu M, Nagy P, Szollosi J . Chemoprevention of Breast Cancer by Dietary Polyphenols. Molecules. 2015; 20(12):22578-620. PMC: 6332464. DOI: 10.3390/molecules201219864. View

Ge L, Li Q, Wang M, Ouyang J, Li X, Xing M . Nanosilver particles in medical applications: synthesis, performance, and toxicity. Int J Nanomedicine. 2014; 9:2399-407. PMC: 4037247. DOI: 10.2147/IJN.S55015. View

Kalra A, Kim J, Klinz S, Paz N, Cain J, Drummond D . Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014; 74(23):7003-13. DOI: 10.1158/0008-5472.CAN-14-0572. View

Ekstrom A, Serafini M, Nyren O, Wolk A, Bosetti C, Bellocco R . Dietary quercetin intake and risk of gastric cancer: results from a population-based study in Sweden. Ann Oncol. 2010; 22(2):438-43. PMC: 3030468. DOI: 10.1093/annonc/mdq390. View

Bravo L . Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev. 1998; 56(11):317-33. DOI: 10.1111/j.1753-4887.1998.tb01670.x. View

10.

Rhee M, Valencia P, Rodriguez M, Langer R, Farokhzad O, Karnik R . Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv Mater. 2011; 23(12):H79-83. PMC: 3123733. DOI: 10.1002/adma.201004333. View

11.

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

12.

Brandl M . Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev. 2001; 7:59-85. DOI: 10.1016/s1387-2656(01)07033-8. View

13.

Manach C, Scalbert A, Morand C, Remesy C, Jimenez L . Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004; 79(5):727-47. DOI: 10.1093/ajcn/79.5.727. View

14.

Nunez C, Estevez S, Del Pilar Chantada M . Inorganic nanoparticles in diagnosis and treatment of breast cancer. J Biol Inorg Chem. 2018; 23(3):331-345. DOI: 10.1007/s00775-018-1542-z. View

15.

DeFrates K, Markiewicz T, Gallo P, Rack A, Weyhmiller A, Jarmusik B . Protein Polymer-Based Nanoparticles: Fabrication and Medical Applications. Int J Mol Sci. 2018; 19(6). PMC: 6032199. DOI: 10.3390/ijms19061717. View

16.

Alphandery E . Natural Metallic Nanoparticles for Application in Nano-Oncology. Int J Mol Sci. 2020; 21(12). PMC: 7352233. DOI: 10.3390/ijms21124412. View

17.

Gupta P, Jani K, Yang D, Sadoqi M, Squillante E, Chen Z . Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. Expert Opin Drug Metab Toxicol. 2016; 12(3):281-9. DOI: 10.1517/17425255.2016.1145655. View

18.

Murawala P, Tirmale A, Shiras A, Prasad B . In situ synthesized BSA capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells. Mater Sci Eng C Mater Biol Appl. 2013; 34:158-67. DOI: 10.1016/j.msec.2013.09.004. View

19.

Simonet S, Rodriguez-Lafrasse C, Beal D, Gerbaud S, Malesys C, Tillement O . Gadolinium-Based Nanoparticles Can Overcome the Radioresistance of Head and Neck Squamous Cell Carcinoma Through the Induction of Autophagy. J Biomed Nanotechnol. 2020; 16(1):111-124. DOI: 10.1166/jbn.2020.2871. View

20.

Daldrup-Link H, Golovko D, Ruffell B, DeNardo D, Castaneda R, Ansari C . MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011; 17(17):5695-704. PMC: 3166957. DOI: 10.1158/1078-0432.CCR-10-3420. View